JP2016502996A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502996A5
JP2016502996A5 JP2015547077A JP2015547077A JP2016502996A5 JP 2016502996 A5 JP2016502996 A5 JP 2016502996A5 JP 2015547077 A JP2015547077 A JP 2015547077A JP 2015547077 A JP2015547077 A JP 2015547077A JP 2016502996 A5 JP2016502996 A5 JP 2016502996A5
Authority
JP
Japan
Prior art keywords
acid
composition
use according
per
oleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502996A (ja
Filing date
Publication date
Priority claimed from EP12197522.1A external-priority patent/EP2742952A1/en
Application filed filed Critical
Publication of JP2016502996A publication Critical patent/JP2016502996A/ja
Publication of JP2016502996A5 publication Critical patent/JP2016502996A5/ja
Pending legal-status Critical Current

Links

JP2015547077A 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物 Pending JP2016502996A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12197522.1A EP2742952A1 (en) 2012-12-17 2012-12-17 Influenza vaccine composition
EP12197522.1 2012-12-17
PCT/EP2013/077006 WO2014095943A1 (en) 2012-12-17 2013-12-17 Vaccine composition for naive subjects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019049330A Division JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Publications (2)

Publication Number Publication Date
JP2016502996A JP2016502996A (ja) 2016-02-01
JP2016502996A5 true JP2016502996A5 (enExample) 2016-12-01

Family

ID=47358019

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015547077A Pending JP2016502996A (ja) 2012-12-17 2013-12-17 ナイーブな対象のためのワクチン組成物
JP2015547078A Pending JP2016502997A (ja) 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015547078A Pending JP2016502997A (ja) 2012-12-17 2013-12-17 免疫無防備状態の集団において使用するためのワクチン組成物
JP2019049330A Pending JP2019112448A (ja) 2012-12-17 2019-03-18 ナイーブな対象のためのワクチン組成物

Country Status (12)

Country Link
US (2) US11065325B2 (enExample)
EP (4) EP2742952A1 (enExample)
JP (3) JP2016502996A (enExample)
KR (3) KR20210007042A (enExample)
CN (3) CN104884085A (enExample)
AU (2) AU2013360889C1 (enExample)
BR (2) BR112015014243A8 (enExample)
CA (2) CA2895023A1 (enExample)
HK (2) HK1212611A1 (enExample)
MX (2) MX2015007753A (enExample)
RU (2) RU2661407C2 (enExample)
WO (2) WO2014095944A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130243817A1 (en) * 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions
ES2927797T3 (es) * 2014-09-26 2022-11-11 Seqirus Uk Ltd Vacunación de sujetos inmunocomprometidos
JP2017528511A (ja) 2014-09-26 2017-09-28 セキラス ユーケー リミテッド 免疫低下された被験体のワクチン接種
RU2634247C2 (ru) * 2015-09-28 2017-10-24 Федеральное государственное бюджетное научное учреждение "СЕВЕРО-КАВКАЗСКИЙ ЗОНАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ВЕТЕРИНАРНЫЙ ИНСТИТУТ" (ФГБНУ СКЗНИВИ) Способ стимуляции иммунного ответа и препарат для его осуществления
WO2019108928A1 (en) * 2017-11-30 2019-06-06 Ohio State Innovation Foundation Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
BR112022020792A2 (pt) * 2020-04-16 2022-11-29 Bayer Ag Combinações de compostos ativos e composições fungicidas compreendendo-as
LT4135519T (lt) * 2020-04-16 2024-12-27 Bayer Aktiengesellschaft Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
WO2021209364A1 (en) * 2020-04-16 2021-10-21 Bayer Aktiengesellschaft Active compound combinations and fungicide compositions comprising those
CN112063699B (zh) * 2020-09-16 2021-06-18 成都市疾病预防控制中心 一种用于研究hiv感染者免疫衰老机制的系统
EP4463180A4 (en) * 2022-01-10 2026-06-17 Childrens Medical Ct Corp METHODS AND COMPOSITIONS RELATING TO THE IMMUNIZATION OF DISTINCTIVE IMMUNE PATIENTS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US8410248B2 (en) 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
ES2399386T3 (es) 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
US20050208602A1 (en) 2001-08-10 2005-09-22 Rosen Craig A 89 human secreted proteins
AU2003301843A1 (en) 2002-05-17 2004-06-07 Human Genome Sciences, Inc. 157 human secreted proteins
ES2352671T3 (es) 2002-11-26 2011-02-22 Eurocine Vaccines Ab Nuevo adyuvante a base de amina.
AU2004263037B2 (en) * 2003-08-11 2011-02-10 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Novel vaccine containing adjuvant capable of inducing mucosal immunity
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
EP2292628A3 (en) 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1930025B1 (en) 2005-08-05 2013-05-01 The University of Tokushima ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE
RU2323742C1 (ru) * 2007-02-15 2008-05-10 Государственное учреждение Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова) Способ повышения иммуногенности инактивированной гриппозной вакцины
US8668904B2 (en) * 2007-12-06 2014-03-11 Glaxosmithkline Biologicals S.A. Influenza composition
EP2293814A4 (en) 2008-05-23 2013-02-13 Univ Michigan NANOEMULSION AGENTS
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
US20130178383A1 (en) 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
US20130243817A1 (en) 2010-09-30 2013-09-19 Eurocine Vaccines Ab Vaccine compositions

Similar Documents

Publication Publication Date Title
RU2015129028A (ru) Вакцинная композиция для неиммунизированных индивидуумов
JP2016502997A5 (enExample)
CY1122783T1 (el) Μιγμα λιπαρων οξεων (ομαδα λιπαρων οξεων, ο.λ.ο.) προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων
JP2015524462A5 (enExample)
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
EP3661600A4 (en) FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
RU2017118211A (ru) Питательные композиции, содержащие sn-1(3)-моноацилглицеролы для использования в лечении синдрома мальабсорбции или синдрома недостаточности пищеварения у детей грудного и раннего возраста
JP2016511753A5 (enExample)
JP2017506233A5 (enExample)
JP2020182497A5 (enExample)
PH12015502517B1 (en) Compositions and methods for nutrient delivery
JP2012509292A5 (enExample)
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
WO2014153168A3 (en) Porcine astrovirus sequences and uses thereof
CO2018012463A2 (es) Composición de lípidos en polvo que comprende una mezcla de sal
RU2013120034A (ru) Усовершенствованные композиции вакцин
MX2018010235A (es) Mezclas de bispiribac.
PH12017500740A1 (en) Nutritional supplements containing a peptide component and uses thereof
JP2013516469A5 (enExample)
JP2016502995A5 (enExample)
JP2017109944A5 (enExample)
JP2016086757A5 (enExample)
JP2015214494A5 (enExample)
Омарова Activities of prevention of the viral hepatitis" a"